

# BEIGENE'S INTERNAL PIPELINE

## THREE LATE-STAGE, AND EIGHT EARLY-STAGE CLINICAL ASSETS



ASSETS	PROGRAMS	DOSE ESC.		DOSE EXPANSION		PIVOTAL		FILED	MARKET
		PH1a		PH1b	PH2*	PH2**	PH3		
zanubrutinib (BTK)	monotherapy		R/R MCL (approved in multiple geographies)						
			WM (approved by FDA in the U.S. 09.01.21)						
			R/R MZL (accelerated approval by FDA in the U.S. 09.15.21)						
			WM† (approved in Canada 03.01.21 and Australia 10.07.21; granted a cATU in France <sup>AA</sup> ; received positive CHMP opinion in the EU)						
			R/R MCL, R/R CLL/SLL (conditionally approved by NMPA in China 06.03.20)						
		R/R WM (conditionally approved by NMPA in China 06.18.21)							
		1L CLL/SLL, R/R CLL/SLL							
		Lupus nephritis							
		Previously treated CLL/SLL (ibrutinib acalabrutinib intolerant)							
		combination		+rituximab 1L MCL					
			+abinituzumab R/R FL						
			+lenalidomide +/- ritux. R/R DLBCL						
tislezumab (PD-1)	monotherapy		R/R cHL (approved 12.26.19), 2L+ UC (approved 04.10.20), 2L/3L HCC (approved 06.23.21)						
			2L/3L NSCLC, MSI-H or dMMR solid tumors, 2L ESCC						
			2L ESCC (filing accepted by the FDA in the U.S.)						
		+ chemo		1L HCC					
				R/R NK/T-cell lymphoma					
				1L Sq. NSCLC (approved 01.13.21), 1L non-Sq. NSCLC (approved 06.23.21)					
				1L NPC (filings accepted in China 08.22.21)					
				1L SCLC, Stage III/IIIA NSCLC, Localized ESCC, 1L UC					
				1L GC, 1L ESCC					
		+ pamiparib (PARP)		Solid tumors					
	+ zanubrutinib (BTK)		B-cell malignancies						
pamiparib (PARP)	monotherapy		3L pBRCA+ OC (approved 05.07.21)						
			2L platinum-sensitive OC maintenance						
			1L platinum-sensitive GC maintenance						
			HER2- BRCA mutated breast cancer						
		+ TMZ (chemo)		Solid tumors					
	+ RT/TMZ (RT/chemo)		Solid tumors						
			Glioblastoma						
ociperlimab (TIGIT)	+ tislezumab		1L NSCLC						
			R/M Cervical Cancer, R/M ESCC <sup>A</sup>						
			Solid tumors						
			1L SCLC						
		+ tislezumab + cCRT		Stage III unresectable NSCLC					
		+ tislezumab + chemo		1L NSCLC					
	+ tislezumab + BAT1706		1L HCC						
	+ mirdametinib		B-Raf- or K-RAS/N-RAS-mutated solid tumors						
lifirafenib (BRAF Dimer)									
BGB-A425 (TIM-3)	monotherapy & + tislezumab		Solid tumors						
BGB-A333 (PD-L1)	monotherapy & + tislezumab		Solid tumors						
BGB-A445 (OX40)	+ tislezumab		Solid tumors						
BGB-11417 (BCL-2)	monotherapy & + zanubrutinib		B-cell malignancies						
BGB-10188 (PI3-Kδ)	monotherapy; + tislezumab; + zanubrutinib		B-cell malignancies; Solid tumors						
BGB-15025 (HPK1)	monotherapy & + tislezumab		Advanced solid tumors						
BGB-23339 (TYK2)	monotherapy		Inflammation and Immunity						

\*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. \*\*Confirmatory clinical trials post approval are required for accelerated approvals. † R/R or not suitable for chemo-immunotherapy; <sup>A</sup>R/M: Recurrent / Metastatic; <sup>AA</sup>France cATU (Was granted a cohort Temporary Authorization for Use (cATU), an early access program, for patients with WM by the French National Agency for Medicines and Health Products Safety (ANSM))

# BEIGENE'S COLLABORATIVE PIPELINE

COMPOUND	(TARGET) / PROGRAM	DOSE ESC.	DOSE EXPANSION		PIVOTAL		COMMERCIAL RIGHTS	PARTNER
		PH1a	PH1b	PH2*	PH2**	PH3		
sotorasib	(KRAS G12C)	Solid Tumors, NSCLC, CRC						
pavurutamab <sup>^^</sup>	(BCMA)	MM						
AMG 176	(Mcl-1, SM)	Hematologic malignancies						
AMG 330 <sup>^</sup>	(CD33)	Myeloid malignancies						
AMG 427 <sup>^^</sup>	(FLT3)	AML						
tarlatamab <sup>^^</sup>	(DLL3)	SCLC						
acapatamab <sup>^^</sup>	(PSMA)	Prostate cancer					China	Amgen
AMG 509 <sup>^</sup>	(STEAP1 XmAb)	Prostate cancer						
AMG 199 <sup>^^</sup>	(MUC17)	GC/GEJ						
AMG 650	(oral small molecule)	Solid tumors						
AMG 506	(FAP x 4-1 BB, DARPin®)	Solid tumors						
AMG 994	Bispecific antibody	Solid tumors						
AMG 256	(Anti-PD-1 x IL21 mutein)	Solid tumors						
sitravatinib <sup>†</sup>	(multi-kinase inhibitor) + tislelizumab	NSCLC, RCC, OC, MEL					Asia ex-Japan, AU, NZ	Mirati
	Monotherapy, + tislelizumab	HCC, GC/GEJ						
zanidatamab <sup>††</sup>	(HER2, bispecific antibody) + chemo, + tislelizumab	GEA					Asia ex-Japan, AU, NZ	Zymeworks
	Monotherapy	Biliary tract cancers						
	(HER2, bispecific antibody) + chemo, + tislelizumab	Breast cancer, GC, GEA						
ZW49	(HER2, bispecific ADC)	HER2-expressing cancers					Asia ex-Japan, AU, NZ	Zymeworks
BGB-3245 <sup>1</sup>	(B-RAF)	Solid tumors					Asia ex-Japan	SpringVWorks <sup>1</sup>
SEA-CD70	(anti-CD70)	MDS, AML					Asia ex-Japan, AU, NZ	Seagen
DKN-01	(DKK1) + tislelizumab ± chemo	GC/GEJ					Asia ex-Japan, AU, NZ	Leap Therapeutics
ABI-H0731	(HBV core inhibitor)	Chronic Hepatitis B Virus						
ABI-H2158	(HBV core inhibitor)	Chronic Hepatitis B Virus					China	Assembly Bio
ABI-H3733	(HBV core inhibitor)	Chronic Hepatitis B Virus						

\* Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. \*\*Confirmatory clinical trials post approval are required for accelerated or conditional approvals. <sup>^</sup> BiTE, <sup>^^</sup> HLE BiTE, <sup>†</sup> Mirati is also conducting its own clinical studies with sitravatinib, including the Phase 3 SAPPHERE trial in non-Sq NSCLC. <sup>††</sup> ZW25, AML: acute myeloid leukemia, HLE BiTE: Half-life extended Bi-specific T-cell engagers, GC/GEJ: gastric cancer/gastroesophageal junction, HCC: hepatocellular carcinoma, IND: Investigational New Drug, MEL: melanoma, MM: multiple myeloma, NHL: non-Hodgkin's lymphoma, N/SCLC: non-/small cell lung cancer, OC: ovarian cancer, RCC: renal cell carcinoma, SM: small molecule; 1. By MapKure, a JV with SpringWorks